Contrave Rejected
Posted: Tuesday, 8 February, 2011 | Categories: Slimming Pills
The Food and Drug Administration has paid no heed to the recommendations of its advisory panel for weight loss treatment, Contrave. This is blow for Orexigen Therapeutics, which was confident about the approval of the treatment based on the panel’s recommendations. The FDA usually goes with the recommendation of their panel but not on this occasion.
The FDA had fears over the use of Contrave in the long term and had suggested that a randomized, double blind trial be carried out on a large scale and for a sufficient length of time, in order to assess the risk of cardiovascular incidences.
Contrave is the third drug to be rejected over the year including Qnexa and Lorcaserin and furthermore, Reductil (Meridia) was taken off the market voluntarily by the pharmaceutical company in the United States late last year. It is both a daunting task to face the FDA during such a climate and an exciting one considering there is nothing on the market in the way of successful appetite suppressants. The market is there for the taking with right kind of drug.